The Caspase Cascade

Core Concept

Caspases (cysteine-dependent aspartate-specific proteases) are the executioners of apoptosis. They are synthesized as inactive zymogens (procaspases) and activated in a cascade: initiator caspases (caspase-8, -9, -10) sense death signals and are activated by induced proximity at large signaling complexes (the DISC or the apoptosome); they then cleave and activate executioner caspases (caspase-3, -6, -7), which cleave hundreds of cellular substrates to produce the characteristic apoptotic morphology — chromatin condensation, DNA fragmentation, membrane blebbing, and cell disassembly. The cascade provides amplification, specificity, and a point of no return.

Key Components

• Caspases: Cysteine proteases that cleave after aspartate residues. Named "caspase" = cysteine + aspartate specificity.
• Procaspases: Inactive zymogens with an N-terminal prodomain, a large subunit, and a small subunit.
• Initiator caspases (8, 9, 10): Long prodomains (DED or CARD) that mediate recruitment to activation platforms.
• Executioner caspases (3, 6, 7): Short prodomains; activated by proteolytic cleavage.
• Activation platforms: The DISC (extrinsic) and the apoptosome (intrinsic).
• IAPs (inhibitor of apoptosis proteins): e.g., XIAP, bind and inhibit caspases.
• SMAC/DIABLO: Mitochondrial protein that neutralizes IAPs.
• Key substrates: ICAD/DFF45, lamins, PARP, gelsolin, ROCK1.

Mechanism / How It Works

1. Zymogen synthesis: Caspases are made as inactive procaspases. Their latency is critical — the cell always carries the machinery of its own destruction.
2. Initiator activation by induced proximity: Procaspase-8 is recruited to the DISC (via DED domains) and procaspase-9 to the apoptosome (via CARD domains). High local concentration forces dimerization; dimerized initiator caspases undergo conformational change and autoprocessing into active heterotetramers (two large + two small subunits).
3. Executioner activation by cleavage: Active initiator caspases cleave executioner procaspases at specific aspartate residues, separating the large and small subunits; the subunits dimerize into the active enzyme. Executioners are the workhorses of demolition.
4. Substrate cleavage and morphology:
   • ICAD/DFF45 cleavage releases CAD, which cuts genomic DNA into the 180-bp nucleosomal ladder.
   • Lamins cleavage disassembles the nuclear lamina.
   • PARP cleavage prevents DNA repair and preserves ATP for apoptosis.
   • Gelsolin, ROCK1, and actin regulators cleavage causes membrane blebbing.
   • Phosphatidylserine exposure (via scramblase activation/flippase inhibition) marks the cell for phagocytosis.
5. Regulation: IAPs such as XIAP bind and inhibit caspase-3, -7, and -9. SMAC/DIABLO released from mitochondria (with cytochrome c) neutralizes IAPs, permitting the cascade to proceed.

Energy and Directionality

The cascade is directional and amplifying: one initiator caspase can activate many executioner caspases, each of which cleaves many substrates, so a few upstream events produce thousands of downstream cuts. Proteolysis is ATP-independent for the cleavage reaction itself, but the apoptosis program as a whole requires ATP (for zymogen maintenance, apoptotic body formation, and ordered disassembly); ATP depletion stalls the orderly cascade and can shunt cells into necrosis. Critically, proteolytic activation is irreversible — there is no "de-caspase" to undo a cleavage — which makes caspase activation the biochemical point of no return.

Experimental Evidence / Technique

• Caspase inhibitors: The broad-spectrum inhibitor zVAD-fmk and specific inhibitors (e.g., DEVD for caspase-3) block apoptosis, proving caspases are required.
• FRET-based caspase reporters and fluorogenic substrates (e.g., DEVD-AMC) measure caspase activity in real time in single cells.
• Western blotting detects procaspase cleavage products (e.g., the p17/p12 fragments of caspase-3) as markers of activation.
• Knockout mice: Caspase-3/7 double-knockout mice die perinatally with defective apoptosis (excess neurons), showing executioner caspases are essential.
• Cleaved-PARP and cleaved-caspase-3 immunohistochemistry are standard clinical markers of apoptosis in tumor biopsies.
• Structural studies: Crystal structures of caspase-8 and the XIAP–caspase interaction revealed the induced-proximity and inhibition mechanisms.

How it works

1. Zymogen synthesis: Caspases are made as inactive procaspases. Their latency is critical — the cell always carries the machinery of its own destruction.
2. Initiator activation by induced proximity: Procaspase-8 is recruited to the DISC (via DED domains) and procaspase-9 to the apoptosome (via CARD domains). High local concentration forces dimerization; dimerized initiator caspases undergo conformational change and autoprocessing into active heterotetramers (two large + two small subunits).
3. Executioner activation by cleavage: Active initiator caspases cleave executioner procaspases at specific aspartate residues, separating the large and small subunits; the subunits dimerize into the active enzyme. Executioners are the workhorses of demolition.
4. Substrate cleavage and morphology:
   • ICAD/DFF45 cleavage releases CAD, which cuts genomic DNA into the 180-bp nucleosomal ladder.
   • Lamins cleavage disassembles the nuclear lamina.
   • PARP cleavage prevents DNA repair and preserves ATP for apoptosis.
   • Gelsolin, ROCK1, and actin regulators cleavage causes membrane blebbing.
   • Phosphatidylserine exposure (via scramblase activation/flippase inhibition) marks the cell for phagocytosis.
5. Regulation: IAPs such as XIAP bind and inhibit caspase-3, -7, and -9. SMAC/DIABLO released from mitochondria (with cytochrome c) neutralizes IAPs, permitting the cascade to proceed.

Common confusions

• Initiator vs. executioner activation: Initiators self-activate by dimerization (induced proximity); executioners are activated by cleavage by initiators. Do not merge the two mechanisms.
• Caspases are not kinases: They proteolyze (cut) substrates; they do not phosphorylate. Apoptosis is proteolytic, whereas much of cell-cycle control is phosphorylative.
• Caspase-8 vs. caspase-3: 8 is an initiator (extrinsic); 3 is an executioner (common final pathway).
• IAPs inhibit, SMAC activates (indirectly): IAPs bind and block caspases; SMAC does not activate caspases directly but removes the IAP brake.

Quick review

• Procaspases (inactive) → initiator caspases (8/9/10) activated by dimerization at DISC/apoptosome → cleave executioner caspases (3/6/7) → cleave ICAD, lamins, PARP, cytoskeletal proteins → apoptotic morphology.
• Amplification + irreversibility make the cascade the point of no return; regulated by IAPs (inhibitors) and SMAC/DIABLO (de-repressor).